Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Soleno Therapeutics (SLNO) EBT Margin (2016 - 2025)

Soleno Therapeutics (SLNO) has disclosed EBT Margin for 5 consecutive years, with 47.27% as the latest value for Q4 2025.

  • On a quarterly basis, EBT Margin changed N/A to 47.27% in Q4 2025 year-over-year; TTM through Dec 2025 was 12.74%, a N/A change, with the full-year FY2025 number at 10.97%, down 7611457.0% from a year prior.
  • EBT Margin was 47.27% for Q4 2025 at Soleno Therapeutics, up from 37.67% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 3216.24% in Q1 2025 to a low of 37.67% in Q3 2025.